Japan's national parliament passed a medical bill on Friday to raise co-payments for prescription drugs similar to over-the-counter medicines [1].
The legislation aims to shift more of the financial burden to patients for medications that have comparable non-prescription alternatives. By aligning out-of-pocket expenses, the government seeks to reduce the strain on the national healthcare system and encourage the use of over-the-counter options.
The bill targets approximately 1,100 prescription drugs [1]. These specific medications were identified as being similar to products available without a prescription, meaning patients will now bear additional costs when opting for the prescription version.
According to the legislation, the new co-payment rules are scheduled to take effect in March 2027 [1]. This timeline provides a window for pharmacies and patients to adjust to the updated pricing structures before the changes are implemented.
The Diet's decision reflects a broader effort to manage healthcare spending in a country with a rapidly aging population. By increasing the cost of prescriptions that mirror available retail medicines, the state intends to optimize the allocation of public health funds, ensuring that subsidized care is prioritized for essential treatments that cannot be purchased over the counter.
“Japan's national parliament passed a medical bill to raise co-payments for prescription drugs similar to over-the-counter medicines.”
This policy shift indicates a strategic move by the Japanese government to curb rising healthcare expenditures by reducing the subsidies for 'redundant' prescriptions. By narrowing the price gap between prescription and over-the-counter drugs, the state is incentivizing a behavioral shift in how patients access basic medications, potentially reducing the volume of physician visits for minor ailments.
